|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1ST TIME HERE?.....CLICK THE FLASHING RED BUTTON ON THE LEFT! | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
March 04, 2005The New York Times: F.D.A. Panel Weighs Fate of a Drug for Cancer
LINK: TYSABRI: "Questions about the accelerated approval program were also raised earlier this week when the multiple sclerosis drug Tysabri was at least temporarily pulled from the market by its manufacturers after two patients developed rare brain infections and one died. Tysabri had been approved only three months earlier under accelerated approval."
|